0 88

Cited 11 times in

Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial

 Byeong-Bae Park  ;  Won Seog Kim  ;  Hyeon Seok Eom  ;  Jin Seok Kim  ;  Young Yiul Lee  ;  Suk Joong Oh  ;  Dae Ho Lee  ;  Cheolwon Suh 
 INVESTIGATIONAL NEW DRUGS, Vol.29(1) : 154-160, 2011 
Journal Title
Issue Date
Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; B-Lymphocytes/pathology* ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Deoxycytidine/analogs & derivatives* ; Deoxycytidine/therapeutic use ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Dexamethasone/therapeutic use* ; Disease-Free Survival ; Female ; Humans ; Ifosfamide/administration & dosage ; Ifosfamide/adverse effects ; Ifosfamide/therapeutic use* ; Lymphoma, Non-Hodgkin/drug therapy* ; Lymphoma, Non-Hodgkin/pathology ; Male ; Middle Aged ; Organoplatinum Compounds/administration & dosage ; Organoplatinum Compounds/adverse effects ; Organoplatinum Compounds/therapeutic use* ; Salvage Therapy* ; Treatment Outcome ; Young Adult
Gemcitabine ; Salvage therapy ; Non-Hodgkin’s lymphoma
BACKGROUND: We investigated response rates to and toxicities of gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for the treatment of relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). PATIENTS AND METHODS: Patients with recurrent or refractory diffuse large B-cell lymphoma or mantle cell lymphoma (DLBCL) were eligible for enrollment in this study. Treatment consisted of gemcitabine 1,000 mg/m(2) intravenously (i.v.) on Days 1 and 8, ifosfamide 2,000 mg/m(2) i.v. on Day 1, dexamethasone 40 mg orally on Days 1-4, and oxaliplatin 130 mg/m(2) i.v. on Day 2, every 21 days. The primary goal of treatment was to establish a response rate after three cycles. Afterwards, patients could proceed to high-dose chemotherapy followed by autologous stem cell transplantation (HDC-ASCT) or receive up to six treatment cycles. RESULTS: Twenty-seven eligible patients were evaluated for toxicity and response. The median age of the patients was 54 years (range, 18-75 years), and most had DLBCL. After three cycles, there were four CR (15%) and 10 PR (37%) for an overall response rate (RR) of 52%. Among a total of 88 GIDOX cycles, grade 3 and 4 neutropenia occurred in 33% and 16% of the cycles, respectively. Likewise, grade 3 and 4 thrombocytopenia occurred in 14% and 16% of the cycles, respectively. Two patients (2%) experienced febrile neutropenia, while seven patients (26%) proceeded to HDC-ASCT. CONCLUSIONS: GIDOX is an active salvage regimen for aggressive B-cell NHL and can be tolerated by patients with acceptable toxicity
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.